This site is intended for Healthcare professionals only.

Suven Life Sciences secures two Product Patents in Eurasia and Norway


Suven Life Sciences secures two Product Patents in Eurasia and Norway

Hyderabad : Suven Life Sciences Ltd announces that the grant of one (1) product patent from Eurasia (025136) and one (1) product patent from Norway (339034) corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with Neuro-degenerative diseases and these Patents are valid through 2032 and 2025 respectively.

The granted claims of the patents are from the mechanism of action include the class of selective H3 Inverse agonist compounds and 5HT6 compounds and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neuro-degenerative disorders like Alzheimer’s disease, Attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Major Depressive disorder (MDD), Parkinson and Schizophrenia.

With these new patents, Suven has a total of twenty (20) granted patents from Eurasia and six (6) granted patents from Norway. These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like at Phase-I or Phase-II.

“We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally” says Venkat Jasti, CEO of Suven.

“Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies through the use of GPCR targets. Suven has 3 clinical stage compounds, a Phase 2 undergoing candidate SUVN-502, Phase 1 completed candidate SUVN-G3031 and Phase 1 undergoing candidate SUVN-D4010 for Alzheimer’s disease and Schizophrenia. In addition to that the Company has ten (10) internally-discovered therapeutic drug candidates currently in pre-clinical stage of development targeting conditions such as ADHD, dementia, depression, Huntington’s disease, Parkinson’s disease and pain.



Source: Press Release
0 comment(s) on Suven Life Sciences secures two Product Patents in Eurasia and Norway

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted